This document provides a financial analysis of Retrophin, a biopharmaceutical company, including its market performance, financial summary, valuation metrics, income statement, cash flow, balance sheet, and key company metrics. The analysis includes data from 2014 and estimates for 2015 to 2017.
documents/vol00010-efta01457577-pdf.pdf
{"title":"Retrophin Financial Analysis","key_people":["Robyn Kamauskas"],"document_date":"2015-05-27","document_type":"tabular","key_locations":["United States"],"key_organizations":["Retrophin","Deutsche Bank"]}